Literature DB >> 11237084

Chronic vulvovaginal candidiasis.

P Nyirjesy1.   

Abstract

Frequently ignored by the medical community, chronic vulvovaginal symptoms are relatively common and can frustrating for patients and physicians. Establishing a proper diagnosis will lay the foundation for an effective therapeutic therapeutic plan. Fungal cultures are an important component of the work-up. The most common causes of chronic vaginal symptoms are recurrent vulvovaginal candidiasis (RVVC), vulvar vestibulitis syndrome and irritant dermatitis. In patients with RVVC caused by Candida albicans, host factors may play an important role. Long-term oral antifungal therapy will break the pattern of recurrence in many patients. Infections caused by other species of yeast may be more resistant to standard treatment approaches.

Entities:  

Mesh:

Year:  2001        PMID: 11237084

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  11 in total

1.  Chronic vulvar irritation: could toilet paper be the culprit?

Authors:  Jo Ann Majerovich; Andrea Canty; Baukje Miedema
Journal:  Can Fam Physician       Date:  2010-04       Impact factor: 3.275

2.  Profile of Candida albicans-secreted aspartic proteinase elicited during vaginal infection.

Authors:  Brad N Taylor; Peter Staib; Ayfer Binder; Antje Biesemeier; Miriam Sehnal; Martin Röllinghoff; Joachim Morschhäuser; Klaus Schröppel
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

3.  Supramolecular Chitosan Micro-Platelets Synergistically Enhance Anti-Candida albicans Activity of Amphotericin B Using an Immunocompetent Murine Model.

Authors:  Tiphany Grisin; Christian Bories; Martina Bombardi; Philippe M Loiseau; Valérie Rouffiac; Audrey Solgadi; Jean-Maurice Mallet; Gilles Ponchel; Kawthar Bouchemal
Journal:  Pharm Res       Date:  2017-02-06       Impact factor: 4.200

Review 4.  Treatment for recurrent vulvovaginal candidiasis (thrush).

Authors:  Georga Cooke; Cathy Watson; Laura Deckx; Marie Pirotta; Jane Smith; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

5.  A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans.

Authors:  Arome Solomon Odiba; Olanrewaju Ayodeji Durojaye; Ifeoma Maureen Ezeonu; Anthony Christian Mgbeahuruike; Bennett Chima Nwanguma
Journal:  Infect Drug Resist       Date:  2022-06-17       Impact factor: 4.177

6.  A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization.

Authors:  Nitin B Dobaria; A C Badhan; R C Mashru
Journal:  AAPS PharmSciTech       Date:  2009-07-24       Impact factor: 3.246

Review 7.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Chlorhexidine, clotrimazole, metronidazole and combination therapy in the treatment of vaginal infections.

Authors:  Shahla Mirzaeei; Maryam Zangeneh; Firoozeh Veisi; Somayeh Parsa; Maryam Hematti
Journal:  J Med Life       Date:  2021 Mar-Apr

9.  Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented.

Authors:  Sujit D Rathod; Patricia A Buffler
Journal:  BMC Womens Health       Date:  2014-03-10       Impact factor: 2.809

Review 10.  Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.

Authors:  Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.